Ensem Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ensem Therapeutics, Inc. - overview
Established
2021
Location
-, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2021, Ensem Therapeutics, Inc. operates as a biotechnology research company that develops drugs intended to discover, develop, and commercialize transformative oncology therapies. In April 2022, Ensem Therapeutics, Inc. raised USD 67 million in series A funding led by new investor GGV Capital, with participation from other new investors Pavilion Capital, Cenova Ventures, Mitsui & Co.
Global Investment, Inc. , and CBC Group. As of May 2022, the company is led by its CEO, Sean Cao. Ensem Therapeutics, Inc.
offers the Kinetic EnsembleTM platform that develops small molecule precision medicines for oncology, with expansion into genetic disorders and other disease areas. ENSEM integrates computational, artificial intelligence, and deep learning methodologies with experimental techniques to identify non-obvious binding pockets and accelerate structure-based drug design, with a focus on difficult-to-drug targets. The company will use the series A funding to further advance its Kinetic Ensemble platform and boost its research and development pipeline.
Current Investors
Granite Asia, Mitsui Global Investment, Cenova Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.ensemtx.com
Verticals
Artificial Intelligence
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.